Back to top

Tale of the Tape

Zacks Equity Research

Weakness seen in Genomic Health (GHDX): Stock Tumbles 9.0%

GHDX CBM

Trades from $3
Read Full ArticleHide Full Article
Genomic Health Inc. (GHDX - Free Report) saw a big move last session, as the company’s shares fell nearly 9% on the day. The move came on pretty good volume too with far more shares changing hands than in a normal session. This continues the most recent downtrend for GHDX, as the stock is down nearly 19% since Jan 22.

This medical research company has seen a flat track record when it comes to current year estimate revisions, as there has been no revision on either side over the past few weeks. The consensus for earnings estimate hasn’t been in a trend either. This recent price action is discouraging, so make sure to keep a close watch on this firm in the near future, and especially on earnings estimates following the recent slump.

GHDX currently has a Zacks Rank #5 (Strong Sell) while its Earnings ESP is 0.00%.

Some better-ranked stocks in the Medical Laboratories & Research industry include Affymetrix Inc. , Cambrex Corporation. (CBM - Free Report) and Idenix Pharmaceuticals Inc. . While Cambrex holds a Zacks Rank #1 (Strong Buy), Affymetrix and Idenix Pharmaceuticals carry a Zacks Rank #2 (Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>

 



In-Depth Zacks Research for the Tickers Above


Normally $25 each - click below to receive one report FREE:


Genomic Health, Inc. (GHDX) - free report >>

Cambrex Corporation (CBM) - free report >>